Qaytarish

Insulinga o‘xshash o‘sish omili 1 (IGF-1)

Kod:9056|CPT:84305|LOINC:2484-4

Sinonimlar
ИФР.IGFIGF-1Insulin-like Growth FactorInsulin-like Growth Factor 1SM-C/IGF-1Somatomedin C
KabiInsulinga o‘xshash o‘sish omili I

Tahlil ma'lumotlari

Tadqiqot usuli

  • Immunokimyoluminometrik analiz (ICMA)
  • Ferment immunoanalizi (EIA)

Kutilayotgan natija topshirish vaqti

1 kun

Maxsus tayyorlik

  • Infants younger than 1 year: withhold feeds for 30–40 minutes before blood collection.
  • Children 1–5 years: fast for 2–3 hours prior to the draw.
  • Individuals ≥5 years: fast for 8 hours; water is allowed.
  • Avoid strenuous exercise and emotional stress for 30 minutes before collection.
  • Do not smoke during the 30 minutes preceding specimen collection.
  • High-dose biotin can interfere with the assay; review supplement use and stop biotin for at least 72 hours before collection.

Qanday foydalanish

Insulinga o‘xshash o‘sish omili 1 (IGF-1; Somatomedin C) tahlili hayot davomida uchraydigan o‘sish buzilishlarini baholash va gipofiz funksiyasini tekshirish uchun qo‘llanadi. Doimiy ravishda yuqori IGF-1 GH ortiqligi tashxisini — bolalarda gigantizm yoki kattalarda akromegaliya — qo‘llab-quvvatlaydi va GH bostirish sinovi bilan birgalikda ishlatiladi. IGF-1 GH ajratuvchi gipofiz adenomasi rezeksiyasidan keyingi operatsiyadan keyingi baholash va uzoq muddatli kuzatuvda, shuningdek adyuvant dori yoki nurlanish terapiyasi vaqtida ham yordam beradi. IGF-1 ni o‘lchash GH terapiyasiga javobni kuzatish uchun ishlatilishi mumkin va klinik hamda boshqa laborator ma’lumotlar bilan integratsiya qilinganda GH rezistentligini aniqlashga yordam berishi mumkin.

Cheklovlar

Yagona o‘sish gormoni (GH) o‘lchovlari bilan taqqoslaganda, IGF-1 endogen GH sekretsiyasini ishonchliroq aks ettiradi, chunki GH pulsativ tarzda ajraladi, IGF-1 esa nisbatan barqaror. IGF-1 jigar, skelet mushaklari va boshqa to‘qimalarda GH ga javoban ishlab chiqariladi va suyak hamda yumshoq to‘qimalar o‘sishi va tana tarkibiga ta’sir etuvchi GH ning ko‘plab effektlarini vositachilik qiladi. Qonda aylanuvchi konsentratsiyalar erta bolalikda past bo‘ladi, pubertat cho‘qqisiga ko‘tariladi va keyinchalik kattalik davrida pasayadi. IGF-1 ning pastligi gipopituitarizm yoki gipotireoz, jinsiy steroid yetishmovchiligi yoki surunkali tizimli kasallik kabi holatlar bilan bog‘liq GH sezgirligining pasayishi bilan kechishi mumkin; GH rezistentligining genetik shakllari kam uchraydi. IGF-1 ko‘tarilishi bilan birga GH ortiqligi bolalarda gigantizmga, kattalarda akromegaliyaga olib keladi; bu skeletning ortiqcha o‘sishi, yumshoq to‘qimalarning kengayishi, kardiometabolik asoratlar va umr davomiyligining qisqarishi bilan tavsiflanadi; odatiy etiologiya — gipofiz adenomasidir va samarali dori, jarrohlik yoki nurlanish terapiyasi odatda IGF-1 ni normallashtiradi. IGF-1 konsentratsiyalari gipofizar mittilikni o‘sish va rivojlanishning konstitutsional kechikishidan farqlamaydi.

O'lchov birliging/mL
Referens oraliq
ErkaklarAyollar
87.3–384121–438

Yoshingizga bog'liq

Ko'rsatmalarWorkup of short stature or poor linear growth in children when growth hormone deficiency is suspected., Evaluation of adults with features suggestive of growth hormone deficiency—such as reduced bone mineral density, fatigue, dyslipidemia, or diminished exercise tolerance—acknowledging that IGF-1 is not a standard test for these presentations., Assessment in the context of suspected hypopituitarism., Monitoring response to administered growth hormone; in pediatrics this is used infrequently because growth velocity is preferred., Evaluation for growth hormone excess, including gigantism in children and acromegaly in adults, together with GH suppression testing., Postoperative evaluation following removal of a GH-secreting pituitary adenoma to help confirm completeness of resection., Ongoing monitoring during adjuvant medical or radiation therapy for a GH-secreting pituitary tumor., Long-term follow-up after pituitary surgery to detect tumor recurrence.

Natija og'ishlarining mumkin sabablari

Pasaygan daraja

  • biotin supplementation (high-dose)
  • malnutrition

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm0.5 mL (min 0.2 mL)
Saqlash tayyorlikXona harorati, Sovutilgan, Muzlatilgan

References

Daughaday WH, Hall K, Salmon WD Jr, Van den Brande JL, Van Wyk JJ. On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab. 1987 Nov;65(5):1075-1076. PubMed 3667879

DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia, Pa: WB Saunders Co; 2001:2257-2268.

Pearson OH, Arafah B, Brodkey J. Management of acromegaly. Ann Intern Med. 1981 Aug;95(2):225-227. PubMed 7258874

Pintor C, Loche S, Cella SG, Müller EE, Baumann G. A child with phenotypic Laron dwarfism and normal somatomedin levels. N Engl J Med. 1989 Feb 9;320(6):376-379. PubMed 2913494

Rappaport R, Prevot C, Brauner R. Somatomedin-C and growth in children with precocious puberty: a study of the effect of the level of growth hormone secretion. J Clin Endocrinol Metab. 1987 Dec;65(6):1112-1117. PubMed 3680478

Underwood LE, D'Ercole AJ. Anterior pituitary gland and hypothalamus: Disorders affecting anterior pituitary function. In: Rudolph AM, Hoffman JI, eds. Pediatrics. 18th ed. Norwalk, Conn: Appleton & Lange; 1987:1454-1465.

Watts NB, Keffer JH. Anterior pituitary and hypothalamus. Practical Endocrinology. 4th ed. Philadelphia, Pa: Lea & Febiger; 1989:11-36.